Omics Approach in Rare Disease and the Challenge of Small Numbers of Patients
Many studies have investigated the role of circulating proteins in COVID-19 disease using different proteomics platforms. In this talk, several studies using Olink technology will be presented, for example, on whether angiopoietin 2 is associated with the induction of vascular necroptosis in COVID-19 acute respiratory distress syndrome or whether there are differences between, for example, bacterial sepsis and COVID-19. In addition, to identify the most robust protein markers for the disease and underlying pathways relevant in different conditions, Olink proteomic profiles from two newly recruited COVID-19 studies were combined with those from three previously published COVID-19 studies. For these studies, three Olink panels (Inflammation and Cardiovascular II & III) were compared with 253 unique proteins. Case/control analysis revealed thirteen proteins (CCL16, CCL7, CXCL10, CCL8, LGALS9, CXCL11, IL1RN, CCL2, CD274, IL6, IL18, MERTK, IFNg, and IL18R1) that were differentially expressed in COVID-19 patients in all five studies. Pathway analysis revealed consistent trends in all studies with pathways related to cytokine-cytokine interaction, IL18 signaling, fluid shear stress, and rheumatoid arthritis.
Dr Frank Schmidt, Associated Professor of Biochemistry and Director of the Proteomics Core of Weill Cornell Medicine in Qatar
Dr Houari Abdesselem, Manager, Proteomics Core Facility, Qatar Biomedical Research Institute, Hamad Bin Khalifa University
Dr Stefan Nierkens, Medical Immunologist, Center for Translational Immunology, University Medical Center Utrecht
Moderator: Raza Ahmed, Olink Proteomics